Pharmaceutical Processing

News

Subscribe to Pharmaceutical Processing News

The Lead

SIMPONI Receives FDA Approval for Ulcerative Colitis

May 16, 2013 | Comments

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.

TOPICS:
View Sample

FREE Daily Email Newsletter

J&J's DePuy to End Two Hip Replacement Systems

May 17, 2013 12:05 pm | by The Associated Press | Comments

Johnson & Johnson's DePuy orthopedics business plans to stop selling a couple of hip replacement systems not widely used by doctors. DePuy will discontinue both its Ultamet Metal-on-Metal Articulation and Complete Ceramic-on-Metal Acetabular systems worldwide at the end of August. It made the...

TOPICS:

Impax Labs launches Generic Version of Zomig

May 17, 2013 10:20 am | by The Associated Press | Comments

Impax Laboratories Inc. said Friday it is now selling a generic version of the migraine drug Zomig. Impax is now selling a low-cost generic version of Zomig tablets and orally disintegrating Zomig tablets in two strengths. Zomig, or zolmitriptan, is available in tablet and nasal spray form and as...

FDA Tobacco Chief Speaks at Industry Meeting

May 17, 2013 8:10 am | by MICHAEL FELBERBAUM,AP Tobacco Writer | Comments

Changes in the marketplace have forced the public health community to wrestle with the idea that some tobacco products may pose less of a health risk than others, the new head of the Food and Drug Administration's tobacco control efforts told an industry group on Thursday.

TOPICS:
Advertisement

Halozyme Rises on Pancreatic Cancer Drug Study

May 17, 2013 8:05 am | Comments

Halozyme posted results from an early-stage trial that included its drug PEGPH20 as a treatment for pancreatic cancer. The regimen included PEGPH20 and the cancer drug Gemzar. Halozyme said PEGPH20 may make tumors more vulnerable to treatment by depleting their defenses and changing their metabolism.

TOPICS:

AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's disease

May 17, 2013 8:01 am | Comments

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

TOPICS:

Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.

May 17, 2013 7:57 am | Comments

Oramed Pharmaceuticals Inc. a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application(IND) for ORMD-0801, its oral insulin capsule.

TOPICS:

Stem Cells Recovered from Cloned Human Embryos

May 16, 2013 8:35 am | by MALCOLM RITTER,AP Science Writer | Comments

Scientists have finally recovered stem cells from cloned human embryos, a longstanding goal that could lead to new treatments for such illnesses as Parkinson's disease and diabetes. A prominent expert called the work a landmark, but noted that a different, simpler technique now under development may prove more useful.

Prestige Brands Returns to Profit in Fourth Quarter

May 16, 2013 8:32 am | Comments

Prestige Brands Holdings Inc. returned to a profit in its fiscal fourth quarter, benefiting from lower operating expenses and better sales of over-the-counter health care products. The company, which distributes over-the-counter and household cleaning products like Clear Eyes and PediaCare, reported net income of $19.3 million, or 37 cents per share, for the three months ended March 31.

TOPICS:
Advertisement

Shrinks, Critics Face Off Over Psychiatric Manual

May 16, 2013 8:24 am | by LINDSEY TANNER,AP Medical Writer | Comments

In the new psychiatric manual of mental disorders, grief soon after a loved one's death can be considered major depression. Extreme childhood temper tantrums get a fancy name. And certain "senior moments" are called "mild neurocognitive disorder."

Nordion Signs Contract Manufacturing Agreement with Navidea Biopharmaceuticals

May 16, 2013 8:05 am | Comments

Nordion Inc., a provider of products and services to the global health science market, today announced it has signed a contract manufacturing agreement with Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals.

TOPICS:

Two Companies to Expand Operations in Puerto Rico

May 16, 2013 7:58 am | Comments

Gov. Alejandro Garcia Padilla says CooperVision will invest $250 million to build 15 new production lines, a project that will create some 350 new jobs. The company currently employs 1,600 workers at a plant in the southern town of Juana Diaz

TOPICS:

Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors

May 16, 2013 7:56 am | Comments

Valeant Pharmaceuticals International, Inc. announced that Dr. Laurence Paul has resigned from Valeant's Board of Directors due to expanded business, philanthropic, and personal commitments. Dr. Paul was originally elected to Biovail Corporation's Board of Directors in June 2002 where he served in several capacities.

TOPICS:

Study Estimates Early Retirees Will Need $226,000 More to Cover Health Care Costs

May 15, 2013 8:51 am | Comments

A new study evaluating the impact of aging on health care costs from birth until very old age determines that the average 55-year-old retiree will spend $226,000 more on health care than a person retiring at age 65, assuming they both live to age 85.

Dr. Reddy's Labs Fourth Quarter Net Income Rises 67%

May 15, 2013 8:45 am | Comments

Dr. Reddy's Laboratories Ltd. said Tuesday its net income climbed 67 percent in the fiscal fourth quarter. The company said it earned 5.7 billion rupees ($104 million), or 60 cents per U.S. share. Its revenue grew 26 percent to 33.4 billion rupees ($611 million)

TOPICS:

Study Questions How Sharply US Should Cut the Salt

May 15, 2013 8:19 am | by LAURAN NEERGAARD,AP Medical Writer | Comments

A surprising new report questions public health efforts to get Americans to sharply cut back on salt, saying it's not clear whether eating super-low levels is worth the struggle. Make no mistake: Most Americans eat way too much salt, not just from salt shakers but because of sodium hidden inside processed foods and restaurant meals.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading